Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 123

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 123
---
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

Year Ended December 31,(in millions, except per share data)202420232022Net sales$16,747 $14,240 $12,682 Cost of products sold5,257 4,345 3,956 Gross profit11,490 9,896 8,727 Operating expenses:Selling, general and administrative expenses5,984 5,190 4,520 Research and development expenses1,615 1,414 1,323 Royalty expense33 46 47 Amortization expense856 828 803 Intangible asset impairment charges386 58 132 Contingent consideration net expense (benefit)(5)58 35 Restructuring net charges (credits)16 69 24 Litigation-related net charges (credits)— (111)173 Loss (gain) on disposal of businesses and assets— — 22  8,887 7,553 7,078 Operating income (loss) 2,603 2,343 1,649 Other income (expense):Interest expense(305)(265)(470)Other, net(16)(93)(38)Income (loss) before income taxes2,282 1,985 1,141 Income tax expense (benefit)436 393 443 Net income (loss)1,846 1,592 698 Preferred stock dividends— (23)(55)Net income (loss) attributable to noncontrolling interests(8)(1)— Net income (loss) attributable to Boston Scientific common stockholders$1,853 $1,570 $642 Net income (loss) per common share — basic$1.26 $1.08 $0.45 Net income (loss) per common share — diluted$1.25 $1.07 $0.45 Weighted-average shares outstandingBasic1,471.5 1,453.0 1,430.5 Diluted1,485.9 1,463.5 1,439.7 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.

66

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIAR